Rodabe N. Amaria

Assistant Professor

The University of Texas MD Anderson Cancer Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Purpose: Intratumoral injection of Clostridium novyi -nontoxic ( C. novyi -NT), lacking alpha-toxin, germinates and subsequently replicates in the tumor hypoxic regions, causing cell lysis and inflammation. This phase Ib study investigated the safety and synergistic effects of pembrolizumab and C. novyi -NT in advanced solid tumors. Patients and Methods: Patients with injectable solid tumors received one intratumoral C. novyi -NT injection (day 8) across four dose cohorts (3 × 10 4 to 100 × 10 4 spores) with pembrolizumab (200 mg intravenously every 3 weeks, day 0–24 months). Sixteen patients were enrolled with a median age of 62.5 years, and the most common tumor types were breast cancer and melanoma. Results: The combination therapy demonstrated a manageable safety profile, with one grade 3 dose-limiting toxicity of abscess formation and the remainder of treatment-related adverse events in ≥10% of patients being grade 1 or 2 injection site reaction (25%), pyrexia (19%), pruritus (13%), leukopenia (13%), and anemia (13%). The maximum tolerated dose was determined to be pembrolizumab intravenously at 200 mg every 3 weeks and a single dose of 100 × 10 4 C. novyi -NT spores intratumorally on day 8. The confirmed overall objective response rate of 25% was observed among four patients with nonkeratinizing undifferentiated nasopharyngeal squamous carcinoma, human papilloma virus–positive squamous cell carcinoma of the base of the tongue, vulvar melanoma, and chordoma. Among these patients, we obtained three partial responses and one complete response. The median duration of the response was 10.93 months, and stable disease was observed in 69% of patients. Conclusions: This study highlights the potential of the C. novyi -NT and pembrolizumab combination as a promising therapeutic strategy for treatment-refractory solid tumors.

Year:

2025

Supplementary Table S1. Planned dose levels of Clostridium novyi-NT given intratumorally in combination with the PD-1 inhibitor, pembrolizumab at 200mg intravenously every 3 weeks (cycle = 21 days).

Year:

2025

Overcoming resistance to immune checkpoint blockade (ICB) remains a critical unmet need for most cancer patients. Loss of the PTEN tumor suppressor gene activates the PI3K-AKT pathway in multiple cancer types. In melanoma, PTEN loss reduces ICB efficacy in preclinical models and correlates with decreased response rates in patients. The PI3Kβ inhibitor GSK2636771 blocked PI3K-AKT activation, increased immune infiltration, and improved ICB efficacy in PTEN-null melanoma preclinical models. Thus, we conducted a phase I/II study (NCT01458067) to evaluate the safety and efficacy of GSK2636771 with pembrolizumab in patients with advanced cancer and PTEN loss. Of the twenty-seven treated patients, 41% experienced grade 3-4 treatment related adverse events. The overall response rate (ORR) by RECIST 1.1 was 12% and 20% experienced clinical benefit. We present the clinical and translational results from this trial and preclinical experiments comparing PI3K isoforms which identifies PI3Kα as an alternative strategy to reverse resistance to ICB.

Year:

2024

Purpose: Enhanced MAPK pathway signaling and cell-cycle checkpoint dysregulation are frequent in NRAS-mutant melanoma and, as such, the regimen of the MEK inhibitor binimetinib and the selective CDK4/6 inhibitor ribociclib is a rational combination. Patients and Methods: This is a phase Ib/II, open-label study of ribociclib + binimetinib in patients with NRAS-mutant melanoma (NCT01781572). Primary objectives were to estimate the MTD/recommended phase II dose (RP2D) of the combination (phase Ib) and to characterize combination antitumor activity at the RP2D (phase II). Tumor genomic characterization and pharmacokinetics/pharmacodynamics were also evaluated. Results: Ten patients (16.4%) experienced dose-limiting toxicities in cycle 1 of phase Ib. Overall response rate in the phase II cohort (n = 41) for the selected RP2D (binimetinib 45 mg twice daily + ribociclib 200 mg once daily, 21 days on/7 days off) was 19.5% [8/41; 95% confidence interval (CI), 8.8–34.9]. The response rate was 32.5% (13/40; 95% CI, 20.1–48.0) in patients with NRAS mutation with concurrent alterations of CDKN2A, CDK4, or CCND1. Median progression-free survival was 3.7 months (95% CI, 3.5–5.6) and median overall survival was 11.3 months (95% CI, 9.3–14.2) for all patients. Common treatment-related toxicities included creatine phosphokinase elevation, rash, edema, anemia, nausea, diarrhea, and fatigue. Pharmacokinetics and safety were consistent with single-agent data, supporting a lack of drug–drug interaction. Conclusions: Ribociclib + binimetinib can be safely administered and is clinically active in patients with NRAS-mutant melanoma. Co-mutations of cell-cycle genes may define a population with greater likelihood of treatment benefit. See related commentary by Moschos, p. 2977

Year:

2022

Collaborators (22)

Kanwal Raghav

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Michael A. Davies

-

UNITED STATES
View details

Aung Naing

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jennifer L. McQuade

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Apostolia M. Tsimberidou

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Anthony P. Conley

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sarina Piha-Paul

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

J. Jack Lee

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Siqing Fu

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Jennifer A. Wargo

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Elizabeth Burton

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David S. Hong

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Han Liang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ana Aparicio

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Sumit Subudhi

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Yitao Tang

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Senthil Damodaran

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Alexander Lazar

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Khashayarsha Khazaie

Professor and Consultant

Mayo Clinic Arizona

UNITED STATES
View details

Timothy Yap

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Weiyi Peng

Director

University of Houston

UNITED STATES
View details